JP2022549791A - ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用 - Google Patents

ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用 Download PDF

Info

Publication number
JP2022549791A
JP2022549791A JP2022517738A JP2022517738A JP2022549791A JP 2022549791 A JP2022549791 A JP 2022549791A JP 2022517738 A JP2022517738 A JP 2022517738A JP 2022517738 A JP2022517738 A JP 2022517738A JP 2022549791 A JP2022549791 A JP 2022549791A
Authority
JP
Japan
Prior art keywords
protein
amino acid
seq
acid sequence
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549791A5 (https=
Inventor
ヘルムート アダム レーム，バーンド
チェン，シュウシャオン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffith University filed Critical Griffith University
Publication of JP2022549791A publication Critical patent/JP2022549791A/ja
Publication of JP2022549791A5 publication Critical patent/JP2022549791A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022517738A 2019-09-20 2020-09-21 ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用 Pending JP2022549791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2023863A NL2023863B1 (en) 2019-09-20 2019-09-20 Protein particles and uses thereof
NL2023863 2019-09-20
PCT/AU2020/000107 WO2021051153A1 (en) 2019-09-20 2020-09-21 Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof

Publications (2)

Publication Number Publication Date
JP2022549791A true JP2022549791A (ja) 2022-11-29
JP2022549791A5 JP2022549791A5 (https=) 2023-08-29

Family

ID=68425230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517738A Pending JP2022549791A (ja) 2019-09-20 2020-09-21 ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用

Country Status (7)

Country Link
US (1) US20220378894A1 (https=)
EP (1) EP4031170A4 (https=)
JP (1) JP2022549791A (https=)
CN (1) CN115175696A (https=)
AU (1) AU2020349589A1 (https=)
NL (1) NL2023863B1 (https=)
WO (1) WO2021051153A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109078177B (zh) * 2018-08-09 2022-07-08 安徽智飞龙科马生物制药有限公司 一种预防结核病的疫苗及联合用药物和制备方法、应用
CA3218711A1 (en) * 2021-05-13 2022-11-17 Roee Amit Methods and compositions for treatment of viral infection
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法
CN118191298A (zh) * 2022-12-14 2024-06-14 上海索昕生物科技有限公司 一种抗体免疫检测试剂及其制备方法和应用
CN116286682B (zh) * 2022-12-30 2026-04-07 中国农业科学院兰州兽医研究所 O型口蹄疫病毒多表位仿生纳米自组装病毒样颗粒及其制备方法和应用
WO2025106425A1 (en) * 2023-11-13 2025-05-22 University Of Florida Research Foundation, Incorporated Immunogenic composition and uses thereof
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
CN119552230B (zh) * 2024-12-12 2026-03-13 中国人民解放军军事科学院军事医学研究院 一种脂肪酸化修饰的白喉毒素抗原及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209503A1 (en) * 2012-01-20 2013-08-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
CN108159408A (zh) * 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
JP2019526274A (ja) * 2016-07-21 2019-09-19 ヴァック４オール・ピーティーイー・リミテッドＶａｃ４Ａｌｌ Ｐｔｅ． Ｌｔｄ． 抗マラリアワクチンとしてのバイオ融合タンパク質

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
PL196114B1 (pl) * 2002-12-31 2007-12-31 Inst Biotechnologii I Antybiot Ciałka inkluzyjne jako antygeny do doustnej immunizacji zwierząt
CN100999548B (zh) * 2006-01-10 2010-09-08 海南天源康泽医药科技有限公司 白喉毒素突变体crm197及其制备方法
CN102686238A (zh) * 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 具有改善的免疫原性的蛋白质基质疫苗
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
KR20130072201A (ko) * 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
WO2015134402A1 (en) * 2014-03-03 2015-09-11 Scarab Genomics, Llc Enhanced production of recombinant crm197 in e. coli
KR102730367B1 (ko) 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
WO2016172762A1 (en) 2015-04-25 2016-11-03 James Cook University Schistosomiasis vaccine
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
GB201706430D0 (en) 2017-04-24 2017-06-07 Univ Oxford Innovation Ltd Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
KR102893870B1 (ko) 2017-08-23 2025-12-02 그리피스 유니버시티 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
EP3706787A4 (en) * 2017-11-06 2021-10-20 OZQ Pty Ltd VACCINE
US12053519B2 (en) * 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209503A1 (en) * 2012-01-20 2013-08-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
JP2019526274A (ja) * 2016-07-21 2019-09-19 ヴァック４オール・ピーティーイー・リミテッドＶａｃ４Ａｌｌ Ｐｔｅ． Ｌｔｄ． 抗マラリアワクチンとしてのバイオ融合タンパク質
CN108159408A (zh) * 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOSCI. REP., vol. vol.38, issue 5, JPN6024038840, 2018, pages 20180238 - 1, ISSN: 0005554433 *
NANOMEDICINE, vol. vol.14, issue 5, JPN6024038842, 2018, pages 1655 - 1665, ISSN: 0005554432 *

Also Published As

Publication number Publication date
EP4031170A4 (en) 2023-11-15
NL2023863B1 (en) 2021-05-25
US20220378894A1 (en) 2022-12-01
AU2020349589A1 (en) 2022-04-07
WO2021051153A9 (en) 2022-12-29
CN115175696A (zh) 2022-10-11
WO2021051153A1 (en) 2021-03-25
EP4031170A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
JP2022549791A (ja) ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用
US11964010B2 (en) Prefusion coronavirus spike proteins and their use
Chen et al. Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy
JP2023513693A (ja) ＳＡＲＳ－ＣｏＶ－２ワクチン
JP2023524054A (ja) ベータコロナウイルスの予防と治療
US20160368950A1 (en) Immunogenic Compositions and Methods
Liu et al. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants
Freyn et al. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice
Savard et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles
CN105307673A (zh) 用于稳健的体液及细胞免疫应答的亚单位疫苗递送平台
JP2014518620A (ja) リポソーム製剤
US11078491B2 (en) Vaccines against Zika virus based on Zika structure proteins
Zhou et al. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice
Ghasemi et al. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection
US11179460B2 (en) Virus-like particles comprising zika antigen
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
CN101031647B (zh) 在大肠杆菌中制备猪丹毒杆菌表面保护性抗原变体的方法
EP4138901A1 (en) Compositions and methods for inducing immune responses against class i fusion protein viruses
CN115515628A (zh) 腮腺炎和麻疹病毒免疫原及其用途
JP2013545733A (ja) ヒト免疫不全ウィルス（ｈｉｖ）の組換えエンベロープ蛋白質及びそれを含むワクチン
AU2011269729B2 (en) Constrained immunogenic compositions and uses therefor
US20240424087A1 (en) Multiepitope self-assembled nanoparticle vaccine platform (msn-vaccine platform) and uses there of
HK40081102A (en) Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
WO2025097030A1 (en) Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250319